* IRadimed Corp IRMD.OQ IRMD.O is expected to show a
rise in
quarterly revenue when it reports results
* The Winter Springs Florida-based company is expected to
report
a 20.6% increase in revenue to $16.175 million from $13.41
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data. The company's guidance on August 3
2023, for the period ended September 30, was for revenue between
$16.10 million and $16.30 million.
* Refinitiv's mean analyst estimate for IRadimed Corp is
for
earnings of 36 cents per share. The company's EPS guidance on
August 3 2023, for the period ended September 30, was between
$0.36 and $0.38
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for IRadimed
Corp is
$60, above its last closing price of $40.74.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.30 0.31 0.36 Beat 16.1
Mar. 31 2023 0.28 0.28 0.30 Beat 5.9
Dec. 31 2022 0.30 0.30 0.32 Beat 6.7
Sep. 30 2022 0.25 0.25 0.29 Beat 18.4
Jun. 0.24 0.24 0.26 Beat 10.6
30 2022
Mar. 31 2022 0.21 0.21 0.22 Beat 7.3
Dec. 31 2021 0.21 0.21 0.33 Beat 57.1
Sep. 30 2021 0.17 0.17 0.23 Beat 35.3
This summary was machine generated November 1 at 18:19 GMT. All
figures in US dollars unless otherwise stated